瑞丹韦单抗

{{Infobox drug
| drug_name =
| INN =
| type = mab
| image =
| width =
| alt =
| caption =

| mab_type = mab
| source = u
| target = SARS-CoV-2的刺突蛋白

| pronounce =
| tradename = Regkirona
| Drugs.com =
| MedlinePlus =
| licence_EU = yes
| DailyMedID =
| licence_US =
| pregnancy_AU = B2
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = 静脉注射
| class =
| ATCvet =
| ATC_prefix = J06
| ATC_suffix = BD06
| ATC_supplemental =

| legal_AU = S4
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment = ，以商品名Regkirona出售，是一种用于治疗COVID-19的人单克隆抗体。该抗体针对SARS-CoV-2的刺突蛋白。它是由赛特瑞恩（Celltrion）开发的。该药物通过静脉输注（滴注）给药。

最常见的副作用包括输液相关反应，包括过敏反应和过敏性休克。

参考资料
延伸阅读
*
*

外部链接
*